血红蛋白A1c即时检测分析仪是否适用?故事仍在继续
该研究依据CLSI方案、国际质量目标及IFCC/NGSP二级参考测量程序,对六款HbA1c即时检测分析仪进行综合分析与可用性评价。结果显示仅两款(The Lab 001和Cobas B101)符合国际质量标准,两款(A1Care和Innovastar)处于临界水平,两款(QuikReadgo和Allegro)不可接受。
要点
- 六款HbA1c即时检测分析仪中仅The Lab 001和Cobas B101符合IFCC与NGSP国际质量标准。
- A1Care和Innovastar表现处于临界水平,QuikReadgo和Allegro不可接受。
- 四款分析仪在Hb变异体干扰、不精密度或批号间变异性方面表现仍差。
核心结论
- 六款HbA1c即时检测分析仪中仅The Lab 001和Cobas B101符合国际质量标准,A1Care和Innovastar处于临界水平,QuikReadgo和Allegro不可接受。
研究设计与样本
- 研究为针对六款HbA1c即时检测分析仪的综合分析与可用性研究,采用CLSI方案、国际质量目标及IFCC和NGSP二级参考测量程序。
- 研究包括精密度(EP-5和EP-15)、正确度(EP-9)、线性(EP-6)、样本互换性(新鲜、冷冻和冻干样本)及Hb变异体干扰(新鲜和冷冻样本)评价。
主要发现
- 六款分析仪中仅两款在各项性能标准范围内表现达到可接受水平。
- 四款分析仪在Hb变异体干扰、不精密度或批号间变异性方面表现仍差。
关键数值与推荐
- 仅The Lab 001和Cobas B101符合IFCC和NGSP国际质量标准,A1Care和Innovastar为临界,QuikReadgo和Allegro不可接受。
临床怎么用
- 科学和临床界需了解各HbA1c即时检测分析仪的性能信息,以便合理决策其使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Point-of-care (POC) analyzers are playing an increasingly important role in diabetes management but it is essential that we know the performance of these analyzers in order to make appropriate clinical decisions. Whilst there is a growing body of evidence around the more well-known analyzers, there are many 'new kids on the block' with new features, such as displaying the presence of potential Hb-variants, which do not yet have a proven track record. METHODS: The study is a comprehensive analytical and usability study of six POC analyzers for HbA1c using Clinical and Laboratory Standards Institute (CLSI) protocols, international quality targets and certified International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and National Glycohemoglobin Standardization Program (NGSP) Secondary Reference Measurement Procedures (SRMP). The study includes precision (EP-5 and EP-15), trueness (EP-9), linearity (EP-6), sample commutability (fresh, frozen and lyophilized), interference of Hb-variants (fresh and frozen samples). RESULTS: Only two of the six analyzers performed to acceptable levels over the range of performance criteria. Hb-variant interference, imprecision or variability between lot numbers are still poor in four of the analyzers. CONCLUSIONS: This unique and comprehensive study shows that out of six POC analyzers studied only two (The Lab 001 and Cobas B101) met international quality criteria (IFCC and NGSP), two (A1Care and Innovastar) were borderline and two (QuikReadgo and Allegro) were unacceptable. It is essential that the scientific and clinical community are equipped with this knowledge in order to make sound decisions on the use of these analyzers.
引用
- Lenters-Westra E, English E. Are hemoglobin A1c point-of-care analyzers fit for purpose? The story continues. Clin Chem Lab Med. 2020. PMID: 33128524. doi:10.1515/cclm-2020-1308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。